What are Biogen's total assets?

Biogen (BIIB) holds $29.5B in total assets, up 5.2% year over year.

How much debt does Biogen have?

Biogen carries $6.6B in total debt against $18.7B of shareholders' equity, a debt-to-equity ratio of 0.35.

How much cash does Biogen have?

Biogen holds $3.4B in cash and equivalents.

Can Biogen cover its short-term obligations?

Its current ratio is 3.06 — current assets exceed current liabilities.

Where does Biogen's balance sheet data come from?

Every line is extracted from Biogen's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Biogen BIIB Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'25	FY'24	FY'23	FY'22
Cash and cash equivalents	$3.01B+26.7%	$2.38B+126%	$1.05B-69.3%	$3.42B+51.2%
Short-term investments	$807.2M—	$0—	$0-100%	$1.47B-4.4%
Inventories	$145.4M+54.8%	$93.9M+14.9%	$81.7M+287%	$21.1M—
Raw materials	$293.4M-7.7%	$317.8M-25.6%	$426.9M+3.3%	$413.2M+18.2%
Work in process	$1.6B-15.3%	$1.88B-2.3%	$1.93B+156%	$751.9M-7.6%
Finished goods	$424.9M+20.1%	$353.8M+38.5%	$255.4M+27.4%	$200.4M+6.7%
Prepaid expenses and other current assets	$1.12B+49.3%	$752.5M-36.3%	$1.18B-16.6%	$1.42B+91.4%
Income taxes receivable	$693.6M—	——	——	——
Trading assets	$807.2M—	——	——	$1.47B-4.4%
Derivative assets	$400K—	——	——	——
Total current assets	$8.97B+20.3%	$7.46B+8.7%	$6.86B-29.9%	$9.79B+24.6%
Property and equipment, net	$3.06B-4.0%	$3.18B-3.9%	$3.31B+0.3%	$3.3B-3.4%
Accumulated depreciation	$2.93B+9.7%	$2.67B+11.2%	$2.4B+10.9%	$2.17B+7.9%
Operating lease right-of-use assets	$265.4M-25.5%	$356.4M-15.1%	$420M+1,135,135,135,035%	$0.04+27.6%
Goodwill	$6.49B+0.2%	$6.48B+4.2%	$6.22B+8.2%	$5.75B-0.2%
Intangible assets, net	$7.38B-23.9%	$9.69B+15.9%	$8.36B+368%	$1.79B+20.9%
Deferred tax assets	$507.6M+166%	$190.5M-70.3%	$641.8M+1,625%	$37.2M+17.4%
Other non-current assets	$750.6M+33.9%	$560.5M-24.8%	$745M-51.3%	$1.53B-21.2%
Total investment securities	$118.1M—	——	——	——
Available-for-sale securities	$419.5M—	$0-100%	$979.9M+41.1%	$694.4M-20.0%
Equity securities	$118.1M-34.3%	$179.7M-56.9%	$416.8M-47.3%	$791.1M-24.5%
Total assets	$29.44B+5.0%	$28.05B+4.5%	$26.84B+9.3%	$24.55B+2.8%
Accounts payable	$432M+1.8%	$424.2M+5.2%	$403.3M-17.9%	$491.5M-16.6%
Accrued expenses	$2.8B-0.2%	$2.81B+7.0%	$2.62B+4.1%	$2.52B-0.5%
Income taxes payable	$114.8M-79.1%	$548.3M+113%	$257.4M-1.0%	$259.9M+48.8%
Total current liabilities	$3.35B-39.4%	$5.53B+61.0%	$3.43B+4.9%	$3.27B-23.9%
Long-term debt	$6.29B+38.3%	$4.55B-33.0%	$6.79B+8.1%	$6.28B+0.1%
Operating lease liabilities, non-current	$290.4M-13.2%	$334.5M-16.4%	$400M+20.1%	$333M+0.8%
Other non-current liabilities	$748.5M+2.2%	$732.3M-6.2%	$781.1M-17.3%	$944.2M-28.5%
Senior unsecured notes, net	$6.29B-0.1%	$6.3B-9.3%	$6.94B+10.5%	$6.28B-13.6%
Total liabilities	$305.3M-97.3%	$11.33B-5.9%	$12.05B+7.9%	$11.17B-13.6%
Preferred stock	$0—	$0—	$0—	$0—
Common stock	$100K0.0%	$100K0.0%	$100K0.0%	$100K-100.0%
Additional paid-in capital	$863.1M+51.6%	$569.4M+88.2%	$302.5M+313%	$73.3M+7.5%
Retained earnings	$20.55B+6.7%	$19.26B+9.3%	$17.63B+7.1%	$16.47B+18.4%
Accumulated other comprehensive income (loss)	-$182M-33.6%	-$136.2M+11.4%	-$153.7M+6.8%	-$164.9M-54.5%
Treasury stock	$2.98B0.0%	$2.98B0.0%	$2.98B0.0%	$2.98B0.0%
Total stockholders' equity	$18.26B+9.2%	$16.72B+13.0%	$14.8B+10.5%	$13.4B+23.0%
Total liabilities and stockholders' equity	$29.44B+5.0%	$28.05B+4.5%	$26.84B+9.3%	$24.55B+2.8%
Available-for-Sale Debt Securities - Amortized Cost	$807.2M—	——	——	$1.48B-3.8%
Available-for-Sale Debt Securities - Amortized Cost (Due Within One Year)	$807.2M—	——	——	$1.48B-3.8%
Available-for-Sale Debt Securities - Fair Value by Maturity	$1.24B—	——	——	——
Available-for-Sale Debt Securities - Single Maturity Date	$1.24B—	——	——	——
Allowance for Doubtful Accounts	$3M-3.2%	$3.1M+55.0%	$2M-13.0%	$2.3M—
Allowance for Doubtful Accounts Receivable (Current)	$3M-3.2%	$3.1M+55.0%	$2M-13.0%	$2.3M—
Cash, Cash Equivalents, and Marketable Securities	$1.24B—	——	——	$2.18B-10.4%
Available For Sale Securities Debt Securities Current	$807.2M—	$0—	$0-100%	$1.47B-4.4%
Derivatives	$10M—	——	——	——
Due from unconsolidated joint business	$524.6M+13.1%	$464M+6.4%	$435.9M+1.0%	$431.4M+4.6%
Finished goods	$424.9M+20.1%	$353.8M+38.5%	$255.4M+27.4%	$200.4M+6.7%
Other current assets	$1.12B+49.3%	$752.5M-36.3%	$1.18B-16.6%	$1.42B+91.4%
Current Equity Amortized Cost	$227.7M-65.9%	$668.7M-31.8%	$979.9M-13.6%	$1.13B-2.8%
Derivative Assets, Current	$10M—	——	——	——
Equity Securities (FV-NI) - Cost Basis	$227.7M-65.9%	$668.7M-31.8%	$979.9M-13.6%	$1.13B-2.8%
Accumulated Goodwill Impairment Losses	——	——	$0—	$0—
Available-for-Sale Debt Securities - Fair Value (Maturing 1 to 5 Years)	$419.3M—	——	——	$703.7M-19.1%
Deferred Tax Assets and Other Non-Current Assets	$750.6M+33.9%	$560.5M+91.1%	$293.3M+4.5%	$280.7M+34.4%
Equity Amortized Cost	$227.7M-65.9%	$668.7M-31.8%	$979.9M-13.6%	$1.13B-2.8%
Finite-Lived Intangible Assets - Expected Amortization Expense (Year One)	——	——	$480M+174%	$175M-10.3%
Finite Lived Intangible Assets - Gross	$14.07B-0.5%	$14.14B+20.5%	$11.73B+58.2%	$7.42B0.0%
Intangible Assets Gross (Excluding Goodwill)	$15.87B-0.5%	$15.95B+12.0%	$14.23B+90.3%	$7.48B-1.7%
Investments - Amortized Cost Basis	$1.24B—	——	——	$2.2B-9.7%
Net Investment in Lease	$265.4M-25.5%	$356.4M-15.1%	$420M+4.0%	$403.9M+7.6%
Long-term marketable securities	$431.9M—	$0—	$0-100%	$705.7M-20.9%
Deferred tax assets	$292.5M-9.8%	$324.2M-65.1%	$928.6M-24.3%	$1.23B-13.3%
Intangible assets — net	$7.38B-6.4%	$7.88B+34.6%	$5.86B+228%	$1.79B-11.8%
Other intangible assets—net	$9.18B-5.3%	$9.69B+15.9%	$8.36B+352%	$1.85B-16.7%
Operating lease right-of-use assets	$265.4M-25.5%	$356.4M-15.1%	$420M+4.0%	$403.9M+7.6%
Other non-current assets	$750.6M+33.9%	$560.5M-24.8%	$745M-51.3%	$1.53B-21.2%
Operating Lease Right-of-Use Assets in Other Assets	$265.4M-25.5%	$356.4M-15.1%	$420M+4.0%	$403.9M+7.6%
Software and Technology Licenses, Net	$750.6M+33.9%	$560.5M-24.8%	$745M-51.3%	$1.53B-21.2%
Derivative Liability, Current	$56.7M—	——	——	——
Other accrued liabilities	$2.8B-0.2%	$2.81B+7.0%	$2.62B+4.1%	$2.52B-0.5%
Derivative Liabilities - Fair Value	$56.7M—	——	——	——
Restructuring Reserve	——	——	——	$131M—
Contingent Consideration Liability (Non-Current)	$246.4M+11.2%	$221.6M—	——	——
Derivative Liabilities (Non-Current)	$2.2M—	——	——	——
Long-Term Debt - Fair Value	$5.68B+4.4%	$5.44B-13.5%	$6.29B+16.2%	$5.41B-32.4%
Notes Payable - Fair Value	$35M-99.4%	$5.44B-13.5%	$6.29B—	——
Common Stock Par Value Per Share	——	——	$0.000.0%	$0.000.0%
Cumulative Gross Losses and Impairments	——	——	$0—	$0—
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	$100K0.0%	$100K0.0%	$100K0.0%	$100K0.0%
Preferred stock; $0.001 par value; 100 shares authorized; no shares issued and outstanding	$0—	$0—	$0—	$0—
Treasury Stock, Value	$2.98B0.0%	$2.98B0.0%	$2.98B0.0%	$2.98B0.0%
Preferred Stock Par Value Per Share	——	——	$0.000.0%	$0.000.0%
Unrealized Gains on Investments	$200K—	——	$35.5M-74.3%	$138M—
Unrealized Losses on Investments (Before Tax)	$0—	——	——	$20.2M+531%
AOCI - Cash Flow Hedge Reclassification (Next 12 Months)	——	——	——	——
Cumulative Cost Basis	$1.24B+85.3%	$668.7M-31.8%	$979.9M-55.4%	$2.2B-9.7%
Fair Value Measurement Disclosure	$246.4M-52.0%	$512.8M—	$0—	——
Income taxes payable – long-term	$166.4M+6.2%	$156.7M-61.1%	$403.2M-25.6%	$541.7M-18.5%
Allowance for doubtful accounts	$3M-3.2%	$3.1M+55.0%	$2M-13.0%	$2.3M—
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax	$0—	——	——	$20.2M+531%
Gross Unrealized Gains	$200K—	——	——	$300K-25.0%
Total	$1.24B—	——	——	$2.2B-9.7%
Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five	$419.3M—	——	——	$703.7M-19.1%
Due after five years	$12.4M—	——	——	$12.1M-49.6%
Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five	$419.5M—	——	——	$694.4M-20.0%
Due after five years	$12.4M—	——	——	$11.3M-52.5%
Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Amortized Cost	$1.24B—	——	——	——
Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One	$807.2M—	——	——	$1.48B-3.8%
Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One	$807.2M—	——	——	$1.47B-4.4%
Available for sale investments	$1.24B—	——	——	$2.18B-10.4%
Common stock, par value (in dollars per share)	——	——	$00.0%	$00.0%
Deferred income taxes	$507.6M+166%	$190.5M-70.3%	$641.8M+91.8%	$334.7M-51.8%
Derivative Liability, Noncurrent	$2.2M—	——	——	——
Equity Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, Before Tax	$109.6M-77.6%	$489M-13.2%	$563.1M+64.3%	$342.7M+22.7%
Gross Unrealized Gains	$0—	$0—	$0—	$0-100%
Cost	$227.7M-65.9%	$668.7M-31.8%	$979.9M-13.6%	$1.13B-2.8%
Finite-Lived Intangible Assets, Accumulated Amortization	$6.69B+6.9%	$6.25B+6.5%	$5.87B+4.3%	$5.63B+4.5%
2028	——	——	$470M+141%	$195M-7.1%
2030	——	——	$480M+174%	$175M-10.3%
2031	——	——	$495M+200%	$165M-8.3%
Remainder of 2026	——	——	——	——
2027	——	——	$345M+60.5%	$215M-15.7%
2029	——	——	$485M+155%	$190M-2.6%
Gross Carrying Amount	$14.07B-0.5%	$14.14B+20.5%	$11.73B+58.2%	$7.42B0.0%
Foreign currency cash flow hedge gain (loss) to be reclassified during next 15 months	——	——	——	——
Goodwill accumulated impairment losses	——	——	$0—	$0—
Indefinite- lived intangible impairment	$15.87B-0.5%	$15.95B+12.0%	$14.23B+90.3%	$7.48B-1.7%
Inventory, Net Current and Noncurrent	$2.31B-9.4%	$2.55B-2.1%	$2.61B+91.1%	$1.37B+1.0%
Investment in biotechnology companies that are determined to be unconsolidated variable interest entities	$49.8M+111%	$23.6M+43.9%	$16.4M-41.0%	$27.8M+13.0%
Investments Fair Value Disclosure	$118.1M—	——	——	——
Long Term Notes Payable	$6.29B+38.3%	$4.55B-33.0%	$6.79B+8.1%	$6.28B-17.0%
Plan Assets For Deferred Compensation Fair Value Disclosure	$52.2M—	——	——	——
Preferred Stock, Par or Stated Value Per Share	——	——	$00.0%	$00.0%
Share of net profit from sage therapeutics, Percent	——	——	50%—	——
Valuation Allowances And Reserves Balance	$1.21B+10.9%	$1.09B+2.8%	$1.06B+2.6%	$1.04B+10.7%
Remainder of Fiscal Year 2024	——	——	——	——
Remainder of Fiscal Year 2025	——	——	——	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Biogen.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What are Biogen's total assets?: Biogen (BIIB) holds $29.5B in total assets, up 5.2% year over year.
How much debt does Biogen have?: Biogen carries $6.6B in total debt against $18.7B of shareholders' equity, a debt-to-equity ratio of 0.35.
How much cash does Biogen have?: Biogen holds $3.4B in cash and equivalents.
Can Biogen cover its short-term obligations?: Its current ratio is 3.06 — current assets exceed current liabilities.
Where does Biogen's balance sheet data come from?: Every line is extracted from Biogen's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.